MyFinsight

HomeCompareAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Privacy Policy
  • Contact

Follow Us

  • Thread
  • X.com
  • Instagram

© 2026 MyFinsight. All rights reserved.

Recent SEC Filings
10/2NIKE, Inc.(NKE)10/2DARDEN RESTAURANTS INC(DRI)9/30CONAGRA BRANDS INC.(CAG)9/29Carnival Corp Ltd.(CCL)9/29URANIUM ENERGY CORP(UEC)9/29COPART INC(CPRT)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)10/2NIKE, Inc.(NKE)10/2DARDEN RESTAURANTS INC(DRI)9/30CONAGRA BRANDS INC.(CAG)9/29Carnival Corp Ltd.(CCL)9/29URANIUM ENERGY CORP(UEC)9/29COPART INC(CPRT)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)
||
||

Balance Sheets Overview

Current Ratio
138.76%
Quick Ratio
138.76%
Cash Ratio
135.37%
Debt to Asset Ratio
68.26%
Unit: Dollar
Assets Breakdown
    • Non-current prepaid clinical tri...
    • Prepaid expenses and other curre...
    • Prepaid clinical trial costs
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable
    • Others
Balance Sheets
2025-09-30
2025-06-30
Cash and cash equivalents
13,183,259
10,363,714
Prepaid clinical trial costs
81,742
104,447
Prepaid expenses and other current assets
247,927
346,964
Total current assets
13,512,928
10,815,125
Non-current prepaid clinical trial costs
819,721
819,721
Total assets
14,332,649
11,634,846
Short-term debt
0
113,246
Accounts payable
5,431,806
4,968,688
Accrued clinical expenses
2,891,175
5,470,185
Accrued compensation
784,956
602,592
Other accrued liabilities
630,471
922,592
Total current liabilities
9,738,408
12,077,303
Warrant liabilities
44,506
16,690
Total liabilities
9,782,914
12,093,993
Common stock, par value of 0.0001 315,000,000 shares authorized 96,337,119 and 46,579,199 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively
9,618
6,800
Additional paid-in capital
185,310,390
176,293,553
Accumulated deficit
-180,770,273
-176,759,500
Total stockholders' equity
4,549,735
-459,147
Total liabilities and stockholders equity
14,332,649
11,634,846
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

RVPHW Balance Sheet Sankey DiagramSankey diagram visualizing RVPHW balance sheet for the periodCash and cashequivalents$13,183,259 Prepaid expenses andother current assets$247,927 Prepaid clinical trialcosts$81,742 Total current assets$13,512,928 Non-current prepaidclinical trial costs$819,721 Total assets$14,332,649 Total liabilities andstockholders equity$14,332,649 Total liabilities$9,782,914 Total stockholders'equity$4,549,735 Accumulated deficit-$180,770,273 Total currentliabilities$9,738,408 Warrant liabilities$44,506 Additional paid-in capital$185,310,390 Common stock, par valueof 0.0001...$9,618 Accounts payable$5,431,806 Accrued clinicalexpenses$2,891,175 Accrued compensation$784,956 Other accruedliabilities$630,471

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)